The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
The firm is developing and beta-testing a line of guide RNA libraries to support CRISPR-based targeted capture and sequencing approaches.
There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.
The method, called negative enrichment, protects DNA regions of interest prior to degrading the surrounding DNA, making the target fragments easier to read.
As they dig into the data on He Jiankui's genome editing experiment, CRISPR researchers say the work he did raises many scientific questions.
Even as He Jiankui expressed pride in the work he had done to alter the CCR5 genes of twin embryos, researchers and ethicists decried him as misguided.
After acquiring Dharmacon, as well as licensing a wide array of editing technologies, Horizon has built itself into a repository of knowledge and tools.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.
DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.
The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.
In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.